INDIVIOR PLC/S (INVVY) Raised to Hold at Zacks Investment Research
Zacks Investment Research upgraded shares of INDIVIOR PLC/S (OTCMKTS:INVVY) from a sell rating to a hold rating in a research report report published on Tuesday.
According to Zacks, “Indivior PLC operates as a specialty pharmaceutical company. It is engaged in discovering and developing medications and treatment for alcohol addiction, opioid overdose, cocaine intoxication and co-occurring conditions, such as schizophrenia. The Company markets and promotes SUBOXONE (buprenorphine and naloxone) Sublingual Film, SUBOXONE (buprenorphine and naloxone) Sublingual Tablet, and SUBUTEX (buprenorphine) Sublingual Tablet, each buprenorphine-based treatment for opioid. Indivior PLC is based in United States. “
Several other analysts also recently weighed in on INVVY. Jefferies Financial Group downgraded INDIVIOR PLC/S from a buy rating to a hold rating in a research note on Wednesday, November 21st. ValuEngine downgraded INDIVIOR PLC/S from a sell rating to a strong sell rating in a research report on Wednesday, November 21st.
INDIVIOR PLC/S (OTCMKTS:INVVY) last announced its earnings results on Thursday, November 1st. The company reported $0.40 earnings per share for the quarter. The business had revenue of $245.00 million for the quarter. On average, equities analysts forecast that INDIVIOR PLC/S will post 1.63 earnings per share for the current year.
About INDIVIOR PLC/S
Indivior PLC, together with its subsidiaries, develops, manufactures, and sells buprenorphine-based prescription drugs for the treatment of opioid dependence. The company's product pipeline focuses on treating opioid use disorder, alcohol use disorder, overdose rescue, and schizophrenia. It markets and promotes SUBLOCADE injection for subcutaneous use; and SUBOXONE sublingual film, SUBOXONE sublingual tablet, and SUBUTEX sublingual tablet, as well as sells legacy analgesic products that include Temgesic, Burpex, and Buprenex.
Featured Article: How to Use the New Google Finance Tool
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for INDIVIOR PLC/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for INDIVIOR PLC/S and related companies with MarketBeat.com's FREE daily email newsletter.